Contact us

HPAPI CDMO Companies
Highly Potent API Manufacturing Services

Your Trusted Partners for Highly Potent API Manufacturing Services and Development

Applied Filters:4 / HPAPI (PDE = 10 - 100 µg/day)×5 / HPAPI (PDE < 10 µg/day)×Clear All
Showing 70 facilities
White Raven - Legiapark
Belgium

White Raven - Legiapark

White Raven

Fill and finish site dedicated to GMP Formulation and the Aseptic filling of Sterile Liquid Injectables.

Discover our facility

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU)

REGION: Europe

USE: Human

BSL (Biological Safety Level): 1, 2

SERVICES: Manufacturing services, Packaging

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: BIOLOGICS, FDF / DRUG PRODUCTS

Sylentis
Spain

Sylentis

Sylentis

Oligonucleotide manufacturer.

Discover our facility

COMPLIANCE: ICH, FDA (cGMP), ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)

MARKETS: EMA (EU), FDA (USA)

REGION: Europe

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: OLIGONUCLEOTIDES

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Pharmaron API Commercial Synthesis Shaoxing (China)
China

Pharmaron API Commercial Synthesis Shaoxing (China)

Pharmaron

Commercial API Small Molecules /Peptides Synthesis.

Discover our facility

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: NMPA (China), FDA (USA)

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, NMPA (China GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

Pharmaron API Commercial Synthesis Cramlington (UK)
United Kingdom

Pharmaron API Commercial Synthesis Cramlington (UK)

Pharmaron

Commercial API Small Molecules Synthesis.

Discover our facility

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), TGA (Australia)

REGION: Europe

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Pharmaron API Commercial Synthesis Coventry (US)
United States

Pharmaron API Commercial Synthesis Coventry (US)

Pharmaron

Commercial API Small Molecules Synthesis.

Discover our facility

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), MHRA (UK), MFDS (South Korea), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, ECOVADIS

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

REGION: North America

BAG Health Care
Germany

BAG Health Care

BAG Health Care GmbH

Parenteral F&F provider for vials in small to mid sized batches.

Discover our facility

MARKETS: EMA (EU), MHRA (UK), TGA (Australia)

REGION: Europe

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BATCH SIZE: Small, Medium

COMPLIANCE: EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Lifecore Injectables CDMO
United States

Lifecore Injectables CDMO

Lifecore Biomedical

CDMO that manufactures clinical & commercial sterile injectable drug products.

Discover our facility

BSL (Biological Safety Level): 3, 1, 2

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

REGION: North America

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

EVER Pharma Jena GmbH
Germany

EVER Pharma Jena GmbH

EVER Neuro Pharma GmbH

Specialized CDMO for development and production of small molecules injectables.

Discover our facility

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2

THERAPEUTIC AREAS OF EXPERTISE (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (N) Nervous system

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Indena Settala
Italy

Indena Settala

Indena

GMP-compliant and FDA-inspected facility that specializes in complex APIs and high-potent compounds up to OEB 6.

Discover our facility

MARKETS: TGA (Australia), Rest of World, EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India)

BATCH SIZE: Small, Medium, Large

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day)

COMPLIANCE: NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP), FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

Hikal Ltd | Bangalore, India
India

Hikal Ltd | Bangalore, India

Hikal Ltd.

cGMP Process Development, Scale-up and Manufacturing of Small Molecule APIs, NMEs and Intermediates from grams to tones.

Discover our facility

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), COFEPRIS, Halal Research Council, ECOVADIS, TGA (Australia GMP), EMA (EU GMP)

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: COSMETICS, NUTRACEUTICALS, CHEMICAL-SYNTHETIC, SERVICES

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (V06) Nutrients

CARBOGEN AMCIS | Vionnaz
Switzerland

CARBOGEN AMCIS | Vionnaz

CARBOGEN AMCIS

Highly Potent APIs development and small-scale cGMP production including chromatography and lyophilization.

Discover our facility

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)

REGION: Europe

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BATCH SIZE: Small

CARBOGEN AMCIS | Veenendaal
Netherlands

CARBOGEN AMCIS | Veenendaal

CARBOGEN AMCIS

Large scale manufacturing of Cholesterol and Vitamin D analogs.

Discover our facility

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: DIGEMID, BRCGS, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, ECOVADIS, TGA (Australia GMP), TITCK (Turkish Health Authorities), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), SQF (Safe Quality Food), NSF

USE: Human, Veterinary

BSL (Biological Safety Level): 1

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, SERVICES

BATCH SIZE: Small

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+32 more facilities

Create free account
Highly potent APIs (HPAPIs) are transforming therapeutic approaches in oncology, hormone therapy, and rare diseases—but they also present significant challenges in safety, containment, and compliance. That’s why leading pharmaceutical companies turn to experienced HPAPI CDMO companies for safe, scalable, and fully compliant manufacturing.

Specialized providers of highly potent API manufacturing services offer state-of-the-art containment systems, expert process development, and global regulatory alignment—enabling your potent compounds to reach the market safely and efficiently.

How to Choose HPAPI CDMO Companies

When evaluating HPAPI CDMO companies, it’s essential to look beyond standard capabilities. Key selection factors include:

  • Containment infrastructure: OEB 4–5 / OEL
  • Experience with specific molecule classes: oncology APIs, cytotoxics, hormones, steroids, immunosuppressants
  • Dedicated HPAPI suites to avoid cross-contamination
  • Scalability from gram-scale development to multi-kilo commercial batches
  • Specialized cleaning validation protocols and trace-level detection analytics
  • Regulatory track record with HPAPI dossiers (FDA, EMA, PMDA, etc.)

HPAPI manufacturing demands scientific precision and engineering excellence—not just compliance, but mastery.

Key Services Offered by Highly Potent API Manufacturing Services Providers

Top-tier highly potent API manufacturing services typically include:

  • Process development and optimization under high-containment
  • Small- and large-scale synthesis of cytotoxic and hormone APIs
  • Technology transfer and scale-up in closed, contained systems
  • Analytical method development including trace-level impurity detection
  • Solid handling and micronization under containment
  • Stability studies and cleaning validation
  • GMP documentation and batch record support
  • Support for regulatory submissions across major markets

These services help you ensure that HPAPI manufacturing is safe, efficient, and globally compliant.

Advantages of Partnering with HPAPI CDMO Companies

Collaborating with specialized HPAPI CDMO companies offers multiple strategic and operational benefits:

  • Operator and environmental safety through advanced containment
  • Faster development with proven HPAPI platforms and process templates
  • High-yield synthesis with impurity control
  • Lower risk of cross-contamination through dedicated HPAPI areas
  • Regulatory readiness with validated processes and audit-proven sites

With the right partner, you can confidently develop and manufacture potent compounds without compromising safety or speed.

HPAPI CDMO Companies

Some of the leading HPAPI CDMO companies include:

  • Glatt Pharmaceutical Services GmbH Co. & KG: cGMP-compliant CDMO for end-to-end services in the complex oral solids dosage forms field. [See CDMO profile]

  • Adragos Pharma: With over 100 years of experience, we have a track record of providing first class service and customer focused manufacturing. [See CDMO profile]

  • BAG Health Care: Parenteral F&F provider for vials in small to mid sized batches and investigational products. [See CDMO profile]

  • i+Med: Developer and manufacturer of new drug products with control release technologies. [See CDMO profile]

  • CARBOGEN AMCIS: Highly Potent APIs development and small-scale cGMP production including chromatography and lyophilization. [See CDMO profile]

  • Apeloa Pharmaceutical Co., Ltd: Development, and manufacturing services for Active Pharmaceutical Ingredients (APIs), Intermediates, and Registered Starting Materials. [See CDMO profile]

  • Mabion cGMP Facility: Development and GMP manufacturing of biotherapeutics, including monoclonal antibodies and any recombinant protein-based products. [See CDMO profile]

  • Shilpa Biologicals Private Limited: Support Process Development, Gene to Cell Line Development to GMP to Formulation Development, Analytical Development, Process Development, Drug Substance, Drug Product, Fill-Finish and Packaging. [See CDMO profile]

  • VIVUNT PHARMA: CDMO Sterile Oncology Drugs. [See CDMO profile]

  • Lannett CDMO: Manufacturing site sits in Seymour, Indiana, and includes capabilities for Oral Solid Dose (OSD) and Liquids. [See CDMO profile]

  • Basic Pharma Manufacturing: Equipped to offer a wide range of analytical testing and regulatory support. These services are tailored to your specific needs, implementing the relevant quality guidelines at every step along the way. [See CDMO profile]

  • Ascendia Pharmaceutical Solutions: GMP-certified CDMO for advanced sterile and non-sterile pharmaceutical manufacturing, formulation development, and analytical testing. [See CDMO profile]

  • Cambrex: Chemical CMO specialized in the early development of small molecule pharmaceutical products. [See CDMO profile]

  • ChemCon: Based in Germany, ChemCon specializes in APIs and fine chemicals, offering expertise in transferring R&D projects into fully cGMP-compliant production processes. [See CDMO profile]

  • Pharmaron: Small molecule manufacturing facilities. [See CDMO profile]

  • Laboratori Alchemia: Custom synthesis of complex products or those which are even unknown in literature. [See CDMO profile]

  • Viswa Laboratories: CRAMS/CDMO, APIs, Intermediates and specialty chemicals, including HPAPI. [See CDMO profile]

  • Actylis: Chemical CDMO for Process Discovery, Development, cGMP, and Commercial Manufacturing Services. [See CDMO profile]

  • Seacross Pharma: With three facilities, Seacross Pharma provides a range of CMO/CDMO custom API services to global clients, including HPAPI. [See CDMO profile]

  • Adare Pharma: Providing turnkey product development through commercial manufacturing expertise, with a strong focus on oral dosage forms for the Pharmaceutical, Animal Health, and OTC markets. [See CDMO profile]

  • Aenova Group: Competence center for conventional solid dosage forms and clinical services, as well as semisolids and liquid pharmaceutical manufacturing. [See CDMO profile]

  • Seda Pharma Development Services: Specialised in integrated Pharmaceutical Development and Clinical Pharmacology, enabling the efficient development of optimal medicinal products from conventional to complex formulations through scientific excellence. [See CDMO profile]

    • Related Information

    You may also be interested in:

    Let MAI CDMO Help You Find the Right HPAPI CDMO Partner

    At MAI CDMO, we connect you with trusted HPAPI CDMO companies offering best-in-class highly potent API manufacturing services—from preclinical scale-up to commercial supply. Whether you’re working with cytotoxics, hormones, or highly active immunomodulators, we’ll help you find a CDMO that meets your potency, regulatory, and timeline requirements.

    Looking to outsource HPAPI manufacturing safely and efficiently? Contact us today to get started.